Harrow Inc (HROW)

$34.93 +3.56 (11.35%)
Market Cap 1.28B
Revenue (ttm) 199.61M
Net Income (ttm) -17.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 188.22
Profit Margin -8.76%
Debt to Equity Ratio 2.01
Volume 903,600
Avg Vol 447,172
Day's Range N/A - N/A
Shares Out 36.69M
Stochastic %K 89%
Beta 0.41
Analysts Strong Sell
Price Target $60.60

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract sur...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 615 733 4730
Address:
1A Burton Hills Boulevard, Suite 200, Nashville, United States
Finnish_boy
Finnish_boy Jul. 13 at 10:43 PM
$HROW "Harrow’s long-term revenue goal of $1B annualized by YE27 looks attainable."- Analyst Steve Seedhouse, Cantor Fitzgerald & Co. SP should be already $75
0 · Reply
Finnish_boy
Finnish_boy Jul. 13 at 8:09 PM
$HROW FY25 total revenue will be >310m.. lets see how much above that. Current guidance is >280m so Harrow adjust it higher during H2.
0 · Reply
Finnish_boy
Finnish_boy Jul. 13 at 6:04 PM
$HROW Okay, i adjust odds higher for acquiring whole MELT at the end (as e.g HROW200 told earlier) after scrolling Cantor report. "Harrow owns 46% of Melt Pharmaceuticals and has indicated they might like to own it entirely. Melt-300 appears superior to I.V. anesthesia for cataract surgery and may be a viable alternative to I.V. anesthesia for other common outpatient procedures (dental, plastic surgery, colonoscopy, vasectomy, etc.). The data look great and the addressable markets frankly look enormous (> 100m annual procedures where Melt-300 could be a viable alternative to I.V. anesthesia)."
0 · Reply
Finnish_boy
Finnish_boy Jul. 13 at 1:50 PM
$HROW This is nice point. Maybe HROW work as hard as they can to scale up Vevye. Vevye has been much better than mgt expected. But have to remember that HROW have small resources so they cant do everything upfront. I think production can be limiting factor again in H2 but it is what is. Patients will try Vevye next year then and we have bigger growth next year. Anyways, H2 will be crazy. See you at $80 level this year. Buckle up!
0 · Reply
Finnish_boy
Finnish_boy Jul. 13 at 12:04 PM
$HROW Klarity-C ended in June. This is one near-term reason why Vevye has skyrocketed when they switch all Klarity-C patients on Vevye. And VAFA is brilliant program bc no need of PAs. Also, cash pay $59 option is affordable if insurance doesnt cover Vevye. You can also opt out if you havent used insurance before on Vevye if i have understood right. Some patients tell that there have been exceptional delays on PhilRX (Vevye demand so high?), but as power2numbers told there will be more production capacity in H2. Vevye will be massive already this year!!!!
3 · Reply
Finnish_boy
Finnish_boy Jul. 13 at 9:55 AM
$HROW Exactly🎯 Vevye is the best drug for mainstream and it expands DED market.
0 · Reply
CFontina
CFontina Jul. 13 at 6:59 AM
$HROW my mom just sent $100,000 to an account I opened for her and she asked me to trade on her behalf. I told her I would buy bonds and treasuries, but I'm thinking about putting it all in HROW. You guys OK with that?
1 · Reply
wallstpirate
wallstpirate Jul. 12 at 1:11 PM
$HROW @Finnish_boy check your email
1 · Reply
Huntergame
Huntergame Jul. 12 at 3:43 AM
$HROW I added more, and on monday I will add more too
0 · Reply
Finnish_boy
Finnish_boy Jul. 11 at 9:19 PM
$HROW I bought more HROW at $34.1 (i sold GLNG).. today we got confirmation that Q2 report will be massive as expected, both Q2 numbers and outlook will be great I couldnt buy the open i was driving a car but it's only couple of dollars difference. Doesnt matter bc this beauty is over $100 in a year. Cantor expects 310m revenue this year🚀i expect more.. lets go
3 · Reply
Latest News on HROW
Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up

Jul 11, 2025, 5:47 PM EDT - 2 days ago

Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up

Harrow: Immense Upside Potential

Jul 9, 2025, 2:52 PM EDT - 4 days ago

Harrow: Immense Upside Potential

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm

Jul 6, 2025, 8:50 PM EDT - 7 days ago

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

Jun 18, 2025, 7:00 AM EDT - 25 days ago

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

I Am Swimming In Dividends With +7% Yields

Jun 13, 2025, 8:30 AM EDT - 4 weeks ago

I Am Swimming In Dividends With +7% Yields

UMH

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Jun 9, 2025, 7:00 AM EDT - 4 weeks ago

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Harrow: Epic Growth & Operating Leverage On Full Display

May 28, 2025, 3:20 PM EDT - 6 weeks ago

Harrow: Epic Growth & Operating Leverage On Full Display

Harrow to Present at Two Investor Conferences in May

May 14, 2025, 7:00 AM EDT - 2 months ago

Harrow to Present at Two Investor Conferences in May

Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

May 10, 2025, 6:17 PM EDT - 2 months ago

Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

Harrow Announces First-Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 2 months ago

Harrow Announces First-Quarter 2025 Financial Results

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

May 5, 2025, 7:00 AM EDT - 2 months ago

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Apr 24, 2025, 10:00 AM EDT - 2 months ago

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Apr 10, 2025, 7:00 AM EDT - 3 months ago

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Mar 29, 2025, 4:30 PM EDT - 3 months ago

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call

Mar 28, 2025, 2:00 PM EDT - 3 months ago

Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp

Mar 28, 2025, 1:39 PM EDT - 3 months ago

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Mar 27, 2025, 4:01 PM EDT - 3 months ago

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Mar 27, 2025, 10:45 AM EDT - 3 months ago

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

Mar 24, 2025, 7:00 AM EDT - 3 months ago

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Mar 17, 2025, 4:01 PM EDT - 4 months ago

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Harrow Launches VEVYE® Access for All

Mar 17, 2025, 7:00 AM EDT - 4 months ago

Harrow Launches VEVYE® Access for All

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Mar 11, 2025, 7:00 AM EDT - 4 months ago

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Mar 3, 2025, 7:15 AM EST - 4 months ago

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025

Mar 1, 2025, 8:50 AM EST - 4 months ago

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

Jan 27, 2025, 7:30 AM EST - 5 months ago

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

COR

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Jan 7, 2025, 7:00 AM EST - 6 months ago

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Those Derisked Baby Bonds Of Harrow, Inc.

Jan 3, 2025, 3:43 PM EST - 6 months ago

Those Derisked Baby Bonds Of Harrow, Inc.

Harrow: The Triesence Relaunch

Dec 14, 2024, 12:09 AM EST - 7 months ago

Harrow: The Triesence Relaunch

Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Nov 21, 2024, 7:00 AM EST - 8 months ago

Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Harrow Announces Participation in Upcoming Investor Conferences

Nov 15, 2024, 7:00 AM EST - 8 months ago

Harrow Announces Participation in Upcoming Investor Conferences

Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 2:56 PM EST - 8 months ago

Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript

Harrow Announces Third Quarter 2024 Financial Results

Nov 13, 2024, 4:34 PM EST - 8 months ago

Harrow Announces Third Quarter 2024 Financial Results

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

Nov 13, 2024, 7:00 AM EST - 8 months ago

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

GDRX

Harrow Announces Market Access Wins for VEVYE®

Nov 12, 2024, 7:00 AM EST - 8 months ago

Harrow Announces Market Access Wins for VEVYE®

Harrow: VEVYE And Its Impact On The DED Market

Nov 11, 2024, 6:37 AM EST - 8 months ago

Harrow: VEVYE And Its Impact On The DED Market

Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow's Branded Eyecare Products

Nov 7, 2024, 7:00 AM EST - 8 months ago

Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow's Branded Eyecare Products

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024

Oct 31, 2024, 7:00 AM EDT - 9 months ago

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024

I Am Banking On The Silver Tsunami With Big Dividends

Oct 12, 2024, 10:30 AM EDT - 9 months ago

I Am Banking On The Silver Tsunami With Big Dividends

THQ XOMA

Harrow Relaunches TRIESENCE®

Oct 3, 2024, 7:00 AM EDT - 10 months ago

Harrow Relaunches TRIESENCE®

Harrow Inc (HROW) Shares Up 3.26% on Oct 2

Oct 2, 2024, 12:10 PM EDT - 10 months ago

Harrow Inc (HROW) Shares Up 3.26% on Oct 2

Harrow Announces Nashville Expansion

Sep 25, 2024, 12:02 PM EDT - 10 months ago

Harrow Announces Nashville Expansion

Harrow to Present at Three Investor Conferences in September in New York

Sep 3, 2024, 7:00 AM EDT - 11 months ago

Harrow to Present at Three Investor Conferences in September in New York

Harrow: Bulls On Parade

Aug 16, 2024, 3:42 PM EDT - 11 months ago

Harrow: Bulls On Parade

Harrow Announces Second Quarter 2024 Financial Results

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Harrow Announces Second Quarter 2024 Financial Results

Don't Buy AI Stocks, Buy The Best Dividend Total Return Stocks

Aug 1, 2024, 3:29 AM EDT - 1 year ago

Don't Buy AI Stocks, Buy The Best Dividend Total Return Stocks

ARLP BEPC BMY BTI BXSL DOW EG

Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024

Jul 25, 2024, 7:00 AM EDT - 1 year ago

Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024

Harrow to Attend 2024 ASRS Annual Meeting

Jul 12, 2024, 7:00 AM EDT - 1 year ago

Harrow to Attend 2024 ASRS Annual Meeting

Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products

Finnish_boy
Finnish_boy Jul. 13 at 10:43 PM
$HROW "Harrow’s long-term revenue goal of $1B annualized by YE27 looks attainable."- Analyst Steve Seedhouse, Cantor Fitzgerald & Co. SP should be already $75
0 · Reply
Finnish_boy
Finnish_boy Jul. 13 at 8:09 PM
$HROW FY25 total revenue will be >310m.. lets see how much above that. Current guidance is >280m so Harrow adjust it higher during H2.
0 · Reply
Finnish_boy
Finnish_boy Jul. 13 at 6:04 PM
$HROW Okay, i adjust odds higher for acquiring whole MELT at the end (as e.g HROW200 told earlier) after scrolling Cantor report. "Harrow owns 46% of Melt Pharmaceuticals and has indicated they might like to own it entirely. Melt-300 appears superior to I.V. anesthesia for cataract surgery and may be a viable alternative to I.V. anesthesia for other common outpatient procedures (dental, plastic surgery, colonoscopy, vasectomy, etc.). The data look great and the addressable markets frankly look enormous (> 100m annual procedures where Melt-300 could be a viable alternative to I.V. anesthesia)."
0 · Reply
Finnish_boy
Finnish_boy Jul. 13 at 1:50 PM
$HROW This is nice point. Maybe HROW work as hard as they can to scale up Vevye. Vevye has been much better than mgt expected. But have to remember that HROW have small resources so they cant do everything upfront. I think production can be limiting factor again in H2 but it is what is. Patients will try Vevye next year then and we have bigger growth next year. Anyways, H2 will be crazy. See you at $80 level this year. Buckle up!
0 · Reply
Finnish_boy
Finnish_boy Jul. 13 at 12:04 PM
$HROW Klarity-C ended in June. This is one near-term reason why Vevye has skyrocketed when they switch all Klarity-C patients on Vevye. And VAFA is brilliant program bc no need of PAs. Also, cash pay $59 option is affordable if insurance doesnt cover Vevye. You can also opt out if you havent used insurance before on Vevye if i have understood right. Some patients tell that there have been exceptional delays on PhilRX (Vevye demand so high?), but as power2numbers told there will be more production capacity in H2. Vevye will be massive already this year!!!!
3 · Reply
Finnish_boy
Finnish_boy Jul. 13 at 9:55 AM
$HROW Exactly🎯 Vevye is the best drug for mainstream and it expands DED market.
0 · Reply
CFontina
CFontina Jul. 13 at 6:59 AM
$HROW my mom just sent $100,000 to an account I opened for her and she asked me to trade on her behalf. I told her I would buy bonds and treasuries, but I'm thinking about putting it all in HROW. You guys OK with that?
1 · Reply
wallstpirate
wallstpirate Jul. 12 at 1:11 PM
$HROW @Finnish_boy check your email
1 · Reply
Huntergame
Huntergame Jul. 12 at 3:43 AM
$HROW I added more, and on monday I will add more too
0 · Reply
Finnish_boy
Finnish_boy Jul. 11 at 9:19 PM
$HROW I bought more HROW at $34.1 (i sold GLNG).. today we got confirmation that Q2 report will be massive as expected, both Q2 numbers and outlook will be great I couldnt buy the open i was driving a car but it's only couple of dollars difference. Doesnt matter bc this beauty is over $100 in a year. Cantor expects 310m revenue this year🚀i expect more.. lets go
3 · Reply
MakeSomeMoneyToday
MakeSomeMoneyToday Jul. 11 at 9:14 PM
$HROW Highest close since January! Let's go !
1 · Reply
BoCap
BoCap Jul. 11 at 4:40 PM
$HROW way under the radar. 50s soon
0 · Reply
JFDI
JFDI Jul. 11 at 4:33 PM
$HROW solid b/o today
0 · Reply
SausageKingOfScranton
SausageKingOfScranton Jul. 11 at 3:29 PM
$HROW $ What’s the price target for this? Any chance of a retrace so I can get my hand on some cheapies?
3 · Reply
Huntergame
Huntergame Jul. 11 at 1:54 PM
$HROW yeah! Finally folks!
0 · Reply
ACNY555
ACNY555 Jul. 11 at 1:47 PM
$HROW Big Dog Cantor with the upgrade!!!!!!!
0 · Reply
Bondra
Bondra Jul. 11 at 1:46 PM
$HROW If you are right finish boy ill swing over from sweden and make you feel real good papi
2 · Reply
Finnish_boy
Finnish_boy Jul. 11 at 1:00 PM
$HROW 🚨Buy all you can!
4 · Reply
JarvisFlow
JarvisFlow Jul. 11 at 12:00 PM
Cantor Fitzgerald has adjusted their stance on Harrow ( $HROW ), setting the rating to Overweight with a target price of 76.
0 · Reply
wallstpirate
wallstpirate Jul. 11 at 11:46 AM
$HROW Cantor give HROW a $76 price target Harrow (HROW) Receives Overweight Rating from Cantor Fitzgerald | HROW Stock News https://www.gurufocus.com/news/2971519/harrow-hrow-receives-overweight-rating-from-cantor-fitzgerald-hrow-stock-news
3 · Reply
wallstpirate
wallstpirate Jul. 11 at 11:04 AM
$HROW @Finnish_boy check your email..
1 · Reply
Finnish_boy
Finnish_boy Jul. 10 at 8:04 PM
$HROW They havent cover any yet. Q2 report can be very pumped.. lets see🚀
1 · Reply